Anti-PDL1/IL10 fusion protein - Pilatus Biosciences
Latest Information Update: 23 Jun 2022
At a glance
- Originator Pilatus Biosciences
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 10 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer